Hepatocellular carcinoma
Conditions
Interventions
A total dose of 32-64 Gy is delivered in 4 fractions over 4-8 days
Sponsors
Division of Radiation Oncology and division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically or radiologically diagnosed hepatocellular carcinoma 2) Single lesion with 5 cm or less in size 3) Ineligible for surgical resection 4) Ineligible for percutaneous local ablative therapy 5) Liver function with Child pugh score 5-6 (class A) or 7-8 (class B) 6) Normal liver volume of 800ml or more 7) Satisfy the liver tolelance dose 8) Dose not exceed the tolelance dose of surrounding normal tissues 9) ECOG Performance Status of 0-2
Exclusion criteria
Exclusion criteria: 1) Uncontrolled ascites 2) Gastric/esophageal varix which needs preventive treatment 3) Tumor thrumbus in main trunk of portal vein or IVC 4) Case with critical complication 5) Simultaneous cancer 6) In pregnancy or with expectation of pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of dose limitting toxicity(DLT) | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor response Local progression free survival Progression free survival Overall survival Adverse effects | — |
Countries
Japan
Contacts
Public ContactHiroshi Mayahara
National Cancer Center Hospital, Tokyo, Japan Division of Radiation Oncology
Outcome results
None listed